MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES

1. A compound of general formula (I) wherein L1 is either aryl or 6-membered heteroaryl, which optionally further includes a heteroatom selected from N, O, and S; L2 is aryl, 5 or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S; or C5-C6 cycloalkyl; R1 is H or independently selected from the group consisting of C1-C2 alkyl, C1-C2 haloalkyl, wherein each of these substituents may optionally be further substituted by one or more substituents selected from the group consisting of halogen, pseudohalogen, hydroxy, amino, or alkyloxy moieties; R2 is H or independently selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl, wherein each of these substituents may optionally be further substituted by one or more substituents selected from the group consisting of halogen, pseudohalogen, hydroxy, amino, or alkyloxy moieties; R3 is H or independently selected from the group consisting of halogen, pseudohalogen, C1-C2 alkyl, C1-C2 haloalkyl, hydroxy or amino moieties; R4 is H or independently selected from the group consisting of halogen, pseudohalogen, C1-C2 alkyl, C1-C2 haloalkyl, methoxy C1-C4 alkyl, thio C1-C4 alkyl, halogen, pseudohalogen, wherein each of these substituents may optionally be further substituted by halogen, pseudohalogen, hydroxy, or amino moiety; R5 is H or independently selected from the one or two groups consisting of C1-C4 alkyl, C1-C4 haloalkyl, methoxy C1-C4 alkyl, thio C1-C4 alkyl, halogen, pseudohalogen, wherein each of these substituents may optionally be further substituted by halogen, pseudohalogen, hydroxy, nitro, or amino moiety; R6 is H or independently selected from C1-C6 alkyl, C1-C4 haloalkyl, methoxy Cl- C4 alkyl, thio C1-C4 alkyl, wherein each of these substituents may optionally be further substituted by halogen, pseudohalogen, hydroxy, nitro, or amino moiety; Y is O, C, N, or S; and n is 0, 1 or 2, as well as any isomers, including geometric, tautomeric and optical forms, as well as mixtures of isomers, including racemic mixtures, and pharmaceutically acceptable derivatives and solvates thereof, for use, as a compound dually acting on two nuclear receptors in prevention or treatment of conditions which are mediated by the action, or by loss of action, of PPARα, PPARγ or FXR receptors or their endogenous ligands, and/or by excessive stimulation of LXRα. 1. Un composé de formule générale (I) dans laquelle L1 est soit aryle, soit hétéroaryle à 6 chaînons, qui comprend éventuellement en outr